Stoke Therapeutics Stock Filter Stocks by Fundamentals
| STOK Stock | USD 11.43 0.16 1.42% |
Stoke Therapeutics fundamentals help investors to digest information that contributes to Stoke Therapeutics' financial success or failures. It also enables traders to predict the movement of Stoke Stock. The fundamental analysis module provides a way to measure Stoke Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Stoke Therapeutics stock.
Stoke | Shares Owned by Institutions |
Stoke Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Stoke Therapeutics from analyzing Stoke Therapeutics' financial statements. These drivers represent accounts that assess Stoke Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Stoke Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 509.0M | 2.1B | 881.4M | 359.0M | 231.4M | 219.8M | |
| Enterprise Value | 286.5M | 1.8B | 738.0M | 247.8M | 46.8M | 44.5M |
Stoke Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Stoke Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Stoke Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Stoke Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Stoke Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Stoke Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Stoke Therapeutics' value.| Shares | Assenagon Asset Management Sa | 2024-09-30 | 1.3 M | Marshall Wace Asset Management Ltd | 2024-06-30 | 1.2 M | Geode Capital Management, Llc | 2024-09-30 | 870.8 K | Granahan Investment Management Inc.. | 2024-09-30 | 645 K | Mpm Oncology Impact Management Lp | 2024-09-30 | 479.5 K | Amvescap Plc. | 2024-06-30 | 437.1 K | Cormorant Asset Management, Llc | 2024-09-30 | 427.2 K | Northern Trust Corp | 2024-09-30 | 339.2 K | Fmr Inc | 2024-09-30 | 322.9 K | Skorpios Trust | 2024-09-30 | 8.9 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 7 M |
Stoke Fundamentals
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.28 | ||||
| Operating Margin | (6.13) % | ||||
| Current Valuation | 368.51 M | ||||
| Shares Outstanding | 52.97 M | ||||
| Shares Owned By Insiders | 4.49 % | ||||
| Shares Owned By Institutions | 95.51 % | ||||
| Number Of Shares Shorted | 6.7 M | ||||
| Price To Book | 2.61 X | ||||
| Price To Sales | 36.16 X | ||||
| Revenue | 8.78 M | ||||
| Gross Profit | 12.4 M | ||||
| EBITDA | (112.3 M) | ||||
| Net Income | (104.7 M) | ||||
| Cash And Equivalents | 275.63 M | ||||
| Cash Per Share | 6.99 X | ||||
| Total Debt | 6.83 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 10.46 X | ||||
| Book Value Per Share | 4.38 X | ||||
| Cash Flow From Operations | (81.07 M) | ||||
| Short Ratio | 13.69 X | ||||
| Earnings Per Share | (2.08) X | ||||
| Price To Earnings To Growth | 0.27 X | ||||
| Target Price | 22.29 | ||||
| Number Of Employees | 110 | ||||
| Beta | 0.95 | ||||
| Market Capitalization | 605.41 M | ||||
| Total Asset | 228.34 M | ||||
| Retained Earnings | (401.85 M) | ||||
| Working Capital | 184.52 M | ||||
| Net Asset | 228.34 M |
About Stoke Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Stoke Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Stoke Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Stoke Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Stoke Therapeutics Piotroski F Score and Stoke Therapeutics Altman Z Score analysis. For more information on how to buy Stoke Stock please use our How to buy in Stoke Stock guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Stoke Therapeutics. If investors know Stoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Stoke Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.08) | Revenue Per Share 0.328 | Quarterly Revenue Growth 0.479 | Return On Assets (0.28) | Return On Equity (0.52) |
The market value of Stoke Therapeutics is measured differently than its book value, which is the value of Stoke that is recorded on the company's balance sheet. Investors also form their own opinion of Stoke Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Stoke Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Stoke Therapeutics' market value can be influenced by many factors that don't directly affect Stoke Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Stoke Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Stoke Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Stoke Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.